These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22811346)

  • 1. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia.
    Wisniewski CS; Robert S
    Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
    Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the safety and tolerability of aripiprazole.
    Pae CU
    Expert Opin Drug Saf; 2009 May; 8(3):373-86. PubMed ID: 19505266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
    Fagiolini A; Brugnoli R; Di Sciascio G; De Filippis S; Maina G
    Expert Opin Pharmacother; 2015 Apr; 16(5):727-37. PubMed ID: 25672664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
    Sokolski KN
    Ann Pharmacother; 2011 Jul; 45(7-8):e36. PubMed ID: 21672885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of aripiprazole in treating mood disorders.
    García-Amador M; Pacchiarotti I; Valentí M; Sanchez RF; Goikolea JM; Vieta E
    Expert Rev Neurother; 2006 Dec; 6(12):1777-83. PubMed ID: 17181424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
    Ono S; Suzuki Y; Shindo M; Endo T; Fukui N; Sugai T; Someya T
    J Clin Pharm Ther; 2012 Jun; 37(3):370-2. PubMed ID: 22023382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.